The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Rein Therapeutics Inc shares valued at $127,593 were purchased by Voss Capital, LP on Nov 14 ’25. At $1.22 per share, Voss Capital, LP acquired 104,183 shares. The insider’s holdings grew to 926,441 shares worth approximately $1.43 million following the completion of this transaction.
Also, Voss Capital, LP purchased 178,392 shares, netting a total of over 247,965 in proceeds. Following the buying of shares at $1.39 each, the insider now holds 500,000 shares.
Before that, Voss Capital, LP had added 97,482 shares to its account. In a trade valued at $133,544, the 10% Owner bought Rein Therapeutics Inc shares for $1.37 each. Upon closing the transaction, the insider’s holdings increased to 97,482 shares, worth approximately $1.27 million.
As published in their initiating research note from H.C. Wainwright on September 22, 2025, Rein Therapeutics Inc [RNTX] has been a Buy and the price target has been revised to $10. Analysts at Rodman & Renshaw started covering the stock with ‘”a Buy”‘ outlook in a report released in late January. As of July 24, 2017, William Blair has initiated its “an Outperform” rating for RNTX. Earlier on July 24, 2017, Jefferies initiated its rating. Their recommendation was “a Buy” for RNTX stock.
Analyzing RNTX Stock Performance
On last trading session, Rein Therapeutics Inc [NASDAQ: RNTX] rose 5.48% to $1.54. The stock’s lowest price that day was $1.45, but it reached a high of $1.56 in the same session. During the last five days, there has been a surge of approximately 22.22%. Over the course of the year, Rein Therapeutics Inc shares have dropped approximately -37.65%. Shares of the company reached a 52-week high of $3.5000 on 01/29/25 and a 52-week low of $1.0400 on 08/04/25.
Support And Resistance Levels for Rein Therapeutics Inc (RNTX)
According to the 24-hour chart, there is a support level at 1.4733, which, if violated, would cause prices to drop to 1.4067. In the upper region, resistance lies at 1.5833. The next price resistance is at 1.6267. RSI (Relative Strength Index) is 57.41 on the 14-day chart, showing neutral technical sentiment.
Is Rein Therapeutics Inc subject to short interest?
Stocks of Rein Therapeutics Inc saw a sharp rise in short interest on 2025-11-14 jumping by 0.45 million shares to 0.48 million. Data from Yahoo Finance shows that the short interest on 2025-10-15 was 26079.0 shares. A jump of 94.56% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 0.22 of the overall float, the days-to-cover ratio (short ratio) jumped to 0.22.
Which companies own the most shares of Rein Therapeutics Inc (RNTX)?
In terms of Rein Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 6 in the next 12 months, up nearly 310.96% from the previous closing price of $1.46. Analysts anticipate Rein Therapeutics Inc stock to reach 6 by 2025, with the lowest price target being 6. On July 24, 2017, BofA/Merrill assigned a price target of “a Buy” to the stock and initiated coverage with a $19.
